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Blake Thomas
University of Northern Iowa 
McNair Director: Dr. Neivita Bueno Watts
Research Mentor: Dr. Jim Hoehns 
 Northeast Iowa Medical Foundation 
 Dr. James Poock
 Dr. Jim Hoehns 
 head research coordinators Jessica 
Schwake BSN RN
 Karrie Cheeseman BSN RN 
 Fasting glucose measurement- a patient making sure not to have 
ate anything in a 24 hour period before checking their blood sugar 
 Titrating- determining the levels in which to raise or lower a 
medication 
 Hemoglobin a1c- a test measuring your average blood glucose 
during the past three months 
 Placebo medication- a medication used to make sure that each 
patient routinely taking their medication 
 Body mass index- weight to height ratio 
 Adverse events- any event that could have possibly led the patient 
into the emergency room
 There is a total of 13 visits 2 of the visits are made through 
telephone calls. The other 11 visits are actual in person encounters 
where the patient will receive a compensation of $50 each time.
 Sanofi sponsored study so this drug manufacturing company will 
gain exposure amongst patients and health professionals
 There can be a possibility that the health professionals with type 2 
diabetes patients can find a more beneficial blood sugar control 
medicine 
 This study strives to deliver innovative solutions
 A commitment to high standards of manufacturing excellence to 
prevent and manage a broad spectrum of medical conditions
 A study working with patients that have type 2 diabetes
 It is an analyzed study to see the difference in quality between  
Sotagliflozin and Glimepiride and to see which one will lower 
patients blood glucose levels more effectively. 
 A 52 week Randomized double- blind double-dummy, active and 
placebo-controlled, parallel group study 
 This study strives to deliver innovative solutions
 Tested drug- Sotagliflozin 400 mg  and 200 mg , given as 200 mg 
tablets 
 Control drug- Glimepiride 1 mg ( starting dose) titrated up to 6 
mg ( glimepiride capsules: 1, 2, and 4 mg dose strengths) 
 Placebo- Sotagliflozin-matching placebo (200 mg) and 
glimepiride-matching placebo
 Screening individuals who could possibly be eligible for the 
clinical study 
 Contact certain publication agency and allow them to know that 
we are holding a clinical research 
 Log in information from visits that have taken place
 Order labs necessary for each visit  
 Type 2 diabetes 
 Taking treatment of stable dose of Metformin at a stable dose of 
1500 mg/day 
 Age 18 years or older
 No Body Mass Index (BMI) <20 or >45 kg/m
 Be able to self monitor and record fasting glucose levels 
 No weight loss medications or  no weight change of 5 kg or more 
during the past 12 weeks 
 Hemoglobin a1c levels between 7.0%-10.0%
 History of drug or alcohol abuse within 6 months prior to 
screening 
 Previous use of any types of insulin >1 month (at any time, except 
for treatment of gestational diabetes)
 History of glucose-6-phosphate dehydrogenase(G6PD) deficiency
 History of severe hypoglycemia resulting unconsciousness, 
seizures or hospitalization within 6 months  
 Identifying other areas that have a high population of certain type 
2 diabetic patients
 Population of age difference with type 2 diabetes 
 Analyzing which hospitals have more use of metformin amongst 
their patients through pharmacy records 
 Having both the study being double blind will give a more 
beneficial and possibly more relevant measure of what medication 
will work best for each patient 
 Keeping track of the blood glucose levels in a journal that is given 
to them will make for more proper measurements to keep record 
on 
 This clinical research that I have been able to be apart of has 
allowed me to analyze certain morbidity of  chronic diseases 
specifically type 2 diabetes. Even with this being a year around 
study the factors needed to be put forth in order to create study . It 
gave me great excitement for my future passions in pursuing a 
graduate level education in Epidemiology.  
